Nathan Slaughter, Chief Investment Strategist of The Daily Paycheck and High-Yield Investing, has developed a long and successful track record over the years by finding profitable investments no matter where they hide. Nathan's previous experience includes a long tenure at AXA/Equitable Advisors, one of the world's largest financial planning firms. He also honed his research skills at Morgan Keegan, where he managed millions in portfolio assets and performed consultative retirement planning services. To reach more investors, Nathan switched gears in 2004 and began writing full-time. He has since published hundreds of articles for a variety of prominent online and print publications. Nathan has interviewed industry insiders like Paul Weisbruch and CEOs like Tom Evans of Bankrate.com, and has been quoted in the Los Angeles Times for his expertise on economic moats. Nathan's educational background includes NASD Series 6, 7, 63, & 65 certifications, as well as a degree in Finance/Investment Management from Sam M. Walton School of Business, where he received a full academic scholarship. When not following the market, Nathan enjoys watching his favorite baseball team, the Cubs, and camping and fishing with his family.
Analyst Articles
In a recent issue of my Energy & Income newsletter, I talked about some maneuvering by congressional Republicans to attach a pipeline amendment to the payroll tax cut bill. The Obama administration had been dragging its heels on this issue and didn’t intend to reach a decision before 2013. Read More
Investing in an undervalued high-growth play brings an inherent challenge. Shares are usually undervalued because the near-term growth prospects aren’t as bright as the long-term prospects. This was the biggest risk factor I laid out when I added Cree Inc. (Nasdaq: CREE) to my $100,000 Real-Money Portfolio. Read More
Long-term investors in McDonald’s (NYSE: MCD) have much to celebrate. The stock delivered returns of 20% a year for the past five years, 15.3% for the past 10 years and 11.4% for the past 15 years. But the Golden Arches could finally be… Read More
Here's a look at six leading players in the game-changing genomics space. Read More
Here are two numbers to consider: 25% and -60%. These numbers should be moving in tandem, so there’s a really good chance the positive number will be sucked back down by the negative number. I’m talking about the stunning rally for dry-bulk shipping stocks and the sharp… Read More
The energy markets are constantly abuzz with activity around the globe. If you’re an investor in this sector — and you should be — then staying abreast of every merger, discovery and seismic report is an exhaustive challenge. But in my Energy & Income newsletter, I stay tuned in… Read More
Just a few short years ago, Williston, North Dakota, was a sleepy little agricultural town with a population of less than 15,000. But thanks to a recent economic boom, Williston has quickly become one of the most fascinating places on the planet. People in this little town… Read More
The investing phrase “Growth at a Reasonable Price,” or GARP for short, likely sums up the ideal backdrop for many investors. Yet many stocks right now appear to possess fairly dim growth prospects and really only appeal to value-oriented investors. Indeed, I added toy maker Hasbro (NYSE: HAS) to… Read More
A key challenge in the pharmaceutical industry these days is the staggering amount of drugs losing their patent protection. Back in November 2011, Pfizer’s (NYSE: PFE) Lipitor — the company’s all-time best-selling drug, which reported annual sales in excess of $10 billion at its peak — lost its patent protection. Read More
There’s nothing like being burned by an investment, and those with money in emerging market stocks learned about it the hard way in 2011. As a group, emerging markets plunged nearly 19%, making them one of the worst-performing… Read More
